Breaking Medical News and In Depth Medical Stories

 
Search News:
     
PROGRAMS
 
 
Elyea may be better than alternatives for diabetic macular edema
Elyea may be better than alternatives for diabetic macular edema (February 23, 2015 - Insidermedicine) From Chicago - New research published in the NEJM finds that for the eye condition diabetic macular edema (DME), the drug aflibercept (Eylea) may be more effective than its alternatives. The researchers found that in DME patients with moderate visual impairment, 20/50 or worse, those receiving aflibercept had an average improvement of 18 letters on a eye chart exam. While those receiving ranibizumab (Lucentis) or bevacizumab (Avastin), had an average improvement of 12 letters.
 
OUR TEAM
More...  
EDITORIAL BOARD
More...